OncoMatch/Clinical Trials/NCT06650566
Study of LM-299 in Subjects Advanced Malignant Tumors
Is NCT06650566 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies LM-299 for malignant tumors.
Treatment: LM-299 — For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable
Cannot have received: anti-tumor treatments
Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-299
Lab requirements
Blood counts
Adequate organ and bone marrow function as defined by protocol.
Kidney function
Liver function
Adequate organ and bone marrow function as defined by protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify